Medpace Holdings, Inc. (MEDP)

NASDAQ: MEDP · Real-Time Price · USD
594.02
+9.11 (1.56%)
Nov 3, 2025, 4:00 PM EST - Market closed
1.56%
Market Cap16.73B
Revenue (ttm)2.36B
Net Income (ttm)432.92M
Shares Out 28.17M
EPS (ttm)14.32
PE Ratio41.48
Forward PE36.31
Dividendn/a
Ex-Dividend Daten/a
Volume271,395
Open584.90
Previous Close584.91
Day's Range572.12 - 596.76
52-Week Range250.05 - 625.00
Beta1.43
AnalystsHold
Price Target451.70 (-23.96%)
Earnings DateOct 22, 2025

About MEDP

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigi... [Read more]

Sector Healthcare
IPO Date Aug 11, 2016
Employees 5,900
Stock Exchange NASDAQ
Ticker Symbol MEDP
Full Company Profile

Financial Performance

In 2024, Medpace Holdings's revenue was $2.11 billion, an increase of 11.84% compared to the previous year's $1.89 billion. Earnings were $404.34 million, an increase of 43.07%.

Financial Statements

Analyst Summary

According to 11 analysts, the average rating for MEDP stock is "Hold." The 12-month stock price target is $451.7, which is a decrease of -23.96% from the latest price.

Price Target
$451.7
(-23.96% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Medpace Analysts Increase Their Forecasts After Upbeat Q3 Earnings

Medpace Holdings Inc. (NASDAQ:MEDP) posted better-than-expected third-quarter earnings on Thursday.

10 days ago - Benzinga

Medpace: Full CRO Model Builds Net Revenue Growth, Maintain At Strong Buy

Medpace Holdings, Inc. continues to deliver robust double-digit revenue growth, with Q3 2025 revenue up 23.7% year-over-year and strong net new business awards. MEDP's full-service CRO model, focused ...

11 days ago - Seeking Alpha

Medpace Holdings, Inc. (MEDP) Q3 2025 Earnings Call Transcript

Medpace Holdings, Inc. (NASDAQ:MEDP) Q3 2025 Earnings Call October 23, 2025 9:00 AM EDT Company Participants Lauren Morris - Associate Director of Investors Relations August Troendle - Chairman & CEO...

11 days ago - Seeking Alpha

Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins

Medpace Holdings Inc. (NASDAQ:MEDP) is trading higher on Thursday after the company released third-quarter earnings.

11 days ago - Benzinga

Medpace Holdings' Good Quarter Is Another Sign Biotech Is Back

The company's new orders soared 49% in the third quarter from a year ago.

11 days ago - Barrons

Six Names, Six Narratives: Optimist Fund's Q3 Performance Map

Wayfair delivered one of its strongest quarters in recent years. ThredUp remains our largest investment. Carvana estimates its U.S. market share is still only about 1.5%.

Other symbols: CVNAFVRRTDUPW
12 days ago - Seeking Alpha

Medpace Holdings, Inc. Reports Third Quarter 2025 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Re...

12 days ago - Business Wire

Medpace Holdings, Inc. to Report Third Quarter 2025 Financial Results on October 22, 2025

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2025 financial results after the market close on Wednesday, October...

5 weeks ago - Business Wire

Medpace: Profit Margin, Growth, And Repurchase Program Will Trump Legislative Headwinds (Rating Upgrade)

For this year, Medpace expects that its revenues will increase by 17.1%, which is an excellent growth rate. From 2019 to Q2 2025, Medpace's outstanding common shares declined by 22.16%, creating value...

6 weeks ago - Seeking Alpha

Medpace: Return Of The Mack, With Double-Digit Revenue Growth

Medpace delivered a stunning Q2 2025, with double-digit revenue and net new awards growth, defying widespread healthcare sector pessimism. The company achieved 14% YoY revenue growth and 18.6% EBITDA ...

3 months ago - Seeking Alpha

Medpace Holdings, Inc. (MEDP) Q2 2025 Earnings Call Transcript

Medpace Holdings, Inc. (NASDAQ:MEDP) Q2 2025 Earnings Conference Call July 22, 2025 9:00 AM ET Company Participants August James Troendle - Chairman & CEO Jesse J. Geiger - President Kevin M.

3 months ago - Seeking Alpha

Medpace's Global CRO Reach Lends Credibility For Its 2025 Revenue Guidance Increase

Medpace's Global CRO Reach Lends Credibility For Its 2025 Revenue Guidance Increase

3 months ago - Seeking Alpha

This Clinical Trials Stock Just Soared 40%. What Caused It to Pop.

If gains hold, that'd be the stock's largest single-day increase on record.

3 months ago - Barrons

Top 2 Health Care Stocks You May Want To Dump This Quarter

As of July 22, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Other symbols: RXRX
3 months ago - Benzinga

Medpace Holdings, Inc. Reports Second Quarter 2025 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Reven...

3 months ago - Business Wire

Medpace Holdings, Inc. to Report Second Quarter 2025 Financial Results on July 21, 2025

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2025 financial results after the market close on Monday, July 21, ...

4 months ago - Business Wire

Medpace Holdings, Inc. (MEDP) Q1 2025 Earnings Call Transcript

Medpace Holdings, Inc. (NASDAQ:MEDP) Q1 2025 Earnings Conference Call April 22, 2025 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive Off...

6 months ago - Seeking Alpha

Medpace Holdings, Inc. Reports First Quarter 2025 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenu...

7 months ago - Business Wire

Medpace Holdings: It Might Be Time To Buy In

Medpace has historically shown incredible growth and strong return metrics. It is currently down 35% from its ATH. The valuation has come down to more favorable levels. Risks include uncertainties aro...

7 months ago - Seeking Alpha

Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, ...

8 months ago - Business Wire

The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation

LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Hold...

8 months ago - Accesswire

Medpace Holdings, Inc. (MEDP) Q4 2024 Earnings Call Transcript

Medpace Holdings, Inc. (NASDAQ:MEDP) Q4 2024 Earnings Conference Call February 11, 2025 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive ...

9 months ago - Seeking Alpha

Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Finan...

9 months ago - Business Wire

Medpace: Impressive Revenue Growth, High ROE Values, And High Growth Potential

Medpace has had an excellent financial performance. Its revenues increased by 495.26% between 2016Q2 and 2024Q3. Meanwhile, its current ROE is 54.08%. The company focused on small and mid-size compani...

9 months ago - Seeking Alpha

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Medpace Holdings, Inc. For Securities Fraud

LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace H...

9 months ago - Accesswire